Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Assessment and Analysis – H1 2017


Published on : Jul 04, 2017

Albany, New York, July 4, 2017: Human CMV (HCMV) is an opportunistic pathogen that poses significant health risks for immunocompromised patients. Therefore, its therapeutic development and assessment is required to control the health risk. To provide exact details about the related therapeutic development, Market Research Hub (MRH) has recently added a study titled as “Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017” to its vast report repository. The research report reviews human cytomegalovirus envelope glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes as well as the targeted therapeutics based on the mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. Moreover, it interacts with host integrin ITGB1, PDGFRA, and EGFR that likely serve as post attachment entry receptors, and also participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. The report cover products from therapy areas such as Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Glioblastoma Multiforme (GBM), Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The report initiates with the human cytomegalovirus envelope glycoprotein B (gB) detailed overview and its therapeutic development, assessment and companies involved. The assessment analysis shows the gB assessment by the mechanism of action, route of administration and molecule type. Further, the report lists the major companies involved in the therapeutic development of human cytomegalovirus envelope glycoprotein that includes Astellas Pharma Inc, Novartis AG, Trellis Bioscience Inc, Vakzine Projekt Management GmbH, VBI Vaccines Inc and Vical Inc.

In the next section, the main drugs of gB therapeutic development are listed along with product description, mechanism of action and R&D progress. The featured drugs include, ASP-0113, CSJ-148, CyMVectin, PPCM, TRL-345, VBI-1501A, VBI-1901, and VPM-2001. Finally, the dormant products, the milestone products and the featured news as well as press releases are analyzed and detailed in the intelligent research for complete evaluation. The report concludes by providing, and hence validating the various resources of the study along with the various tables and figures that help in easy and early decision making by the industry experts.

Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157722

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top